Larvol Delta - Sagimet-Biosciencesannounced-that-its-AURORA-Phase-3-clinical-trial-of-FASN-inhibitor-denifanstat-in-moderate-to-severe-acne-is-on-track-to-initiate-enrollment-in-Q4-2026

denifanstat (TVB-2640) - Sagimet Biosci

https://www.globenewswire.com/news-release/2026/08/25/3350295/0/en/sagimet-biosciences-advances-aurora-u-s-phase-3-trial-of-denifanstat-in-acne-toward-patient-enrollment-in-q4-2026.html

Aug 25, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next